Neupro
(Rotigotine)ApprovedSmall molecule
UCBRotigotine is used to treat Parkinson's disease and restless legs syndrome by helping to restore balance of certain chemicals in the brain that control movement and sensations.[2] Neupro is currently approved and in use across 6 indications[4].[1]
Neupro is one of 154 small molecule programs targeting Parkinson disease. It is currently in Approved.
6
Indications
60
Total Trials
0
Active Trials
153
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
100 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Neupro
UCBApproved
Leqembi
EisaiApproved
Dayvigo
EisaiApproved
Lexapro
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Azilect
TevaApproved
Farxiga
AstraZenecaApproved
Rifadin
SanofiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Restless Legs Syndrome13 trials
Show 10 more trials
Parkinson's Disease11 trials
Show 8 more trials
Idiopathic Parkinson's Disease8 trials
Show 5 more trials
Liver3 trials
18 more indications
ESS2 trials
Treatment2 trials
Itching2 trials
Switching From Oral Dopamine Agonists to Rotigotine
Completed·—·Phase 4·NCT01976871·21 enrolled
Tics1 trial
Parkinson1 trial
Female1 trial
Trial1 trial
Sleep Disorder1 trial
Apathy1 trial
Restless Leg Syndrome1 trial
Fibromyalgia1 trial
Parkinson's Disease (PD)1 trial
Gastrointestinal Dysfunction1 trial
Regulatory
FDA Approval Timeline[5]
Apr 2, 2012
NEUPRO
NDA NDA021829
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Neupro drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rotigotine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Neupro. U.S. Food & Drug Administration.
- [7]